Business Wire

CES Asia 2018 Innovation Awards Call for Judges and Entries Now Open


The Consumer Technology Association (CTA) today announced its call for judges and product entries for CES Asia 2018’s Innovation Awards. Tech experts can submit applications to join the judging panel through March 23, 2018. Products can be submitted for consideration through April 20, 2018.

The CES Asia Innovation Awards program honors new to market products across 20 product categories, including AI, drones, health tech, virtual reality, wearables and more. Products selected will be displayed in the Innovation Awards Showcase at CES Asia and prominently featured on the official CES Asia website. The CES Asia Innovation Awards program is open to CES Asia exhibitors only. Additional program rules and entry qualifications can be found on the CES Asia Innovation Awards webpage.

Recognizing outstanding design and engineering in consumer technology, the CES Asia Innovation Awards program also seeks qualified judges to serve on an elite panel of reviewers. Global technology industry experts, analysts, designers, engineers and members of the media are encouraged to apply. Judges will evaluate each product category on five criteria: engineering qualities, aesthetic qualities, function and user value, unique features and level of innovation. Qualified judges must have an appreciation for outstanding product design and engineering in addition to at least five years of tech industry experience.

For additional inquiries about the CES Asia Innovation Awards program entry and judging, please contact

Owned and produced by CES® and co-produced by Shanghai Intex, CES Asia 2018 will run from June 13-15, in Shanghai, China. The premier event for the consumer technology industry in China, CES Asia showcases major brands and innovative companies across several vertical markets in the Asian marketplace.

For the latest show news, information, photos, b-roll and more, visit

Note to Editors:

High-definition video b-roll from CES Asia 2017 is available for easy download on . Journalists traveling from outside of China will require a J-1 or J-2 visa . For questions about exhibiting at CES Asia, contact Brian Moon at or +1 703-907-4351.

About CES Asia:

Owned and produced by CES® and co-produced by Shanghai Intex Exhibition Co., Ltd (Shanghai Intex), CES Asia is the premier event for the consumer technology industry, showcasing the full breadth and depth of the innovation value-chain in the Asian marketplace. Key global businesses come to this new event to grow and reinforce their brand by showcasing the latest products and technologies to consumer tech industry executives, foreign buyers, international media and a limited number of consumers from China. Attendees have exclusive access to some of the largest brands from China and around the world, while celebrating the innovation that defines the consumer technology sector.

About Consumer Technology Association and CES:

Consumer Technology Association (CTA)™ is the trade association representing the $351 billion U.S. consumer technology industry, which supports more than 15 million U.S. jobs. More than 2,200 companies – 80 percent are small businesses and startups; others are among the world’s best known brands – enjoy the benefits of CTA membership including policy advocacy, market research, technical education, industry promotion, standards development and the fostering of business and strategic relationships. CTA also owns and produces CES® – the world’s gathering place for all who thrive on the business of consumer technologies. Profits from CES are reinvested into CTA’s industry services.

About Shanghai Intex:

Shanghai Intex Exhibition Co., Ltd was originally the exhibition organizing business of Shanghai Intex, a pioneering exhibition organizer established in 1995. Shanghai Intex is jointly overseen by the China Council for the Promotion of International Trade (CCPIT) Shanghai and PNO Exhibition Investment (Dubai) Limited. Starting in 1998, Shanghai Intex has organized over 100 trade shows and conferences with a sum total exhibition space in excess of 2 million sqm. Shanghai Intex is comprised of professional teams with a wealth of experience in organizing major international events, covering the creative industry, healthcare, lifestyle, advanced manufacturing and consumer electronics.


  • CES on the Hill
    April 16, Washington, DC
  • Digital Patriots Dinner
    April 17, Washington, DC
  • CES Asia 2018 – Register
    June 13-15, Shanghai, China
  • CEO Summit
    June 24-27, Barcelona, Spain
  • CES 2019
    January 8-11, 2019

Contact information

Consumer Technology Association
Teresa Hsu, 703-907-5259
Bernice Morquette, 703-907-7651

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 21:28Tiedote

Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (, a leading German electronics publication. This press release features multimedia. View the full release here: Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl

Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 19:05Tiedote

Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 15:52Tiedote

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 15:50Tiedote

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 15:46Tiedote

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 15:00Tiedote

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme